BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
- First Posted Date
- 2002-11-13
- Last Posted Date
- 2011-11-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 738
- Registration Number
- NCT00048581
- Locations
- 🇺🇸
Local Institution, Milwaukee, Wisconsin, United States
Atazanavir for HIV Infected Individuals: An Early Access Program
- Conditions
- HIV Infections
- First Posted Date
- 2002-09-30
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00046345
- Locations
- 🇺🇸
LOcal Instituton, Sarasota, Florida, United States
🇵🇷Local Institution, Rio Piedras, Puerto Rico
🇺🇸local Institution, Fairfax, Virginia, United States
A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy
- Conditions
- Breast Cancer
- First Posted Date
- 2002-05-13
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00036621
- Locations
- 🇺🇸
Local Institution, Green Bay, Wisconsin, United States
A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2002-05-13
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00036608
- Locations
- 🇺🇸
Local investigator, Dallas, Texas, United States
🇺🇸Local Investigator, Richmond, Virginia, United States
Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV
- Conditions
- HIV Infections
- Interventions
- Drug: Lopinavir/ritonavir + tenofovir + nucleoside
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2010-12-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 571
- Registration Number
- NCT00035932
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00035633
- Locations
- 🇺🇸
Local Investigator, Seattle, Washington, United States
🇺🇸Local Institution, San Francisco, California, United States
🇺🇸Investigator Meeting, Providence, Rhode Island, United States
Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
- Conditions
- Graft RejectionKidney TransplantationRenal Transplantation
- Interventions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 230
- Registration Number
- NCT00035555
- Locations
- 🇺🇸
Medical Univ. of South Carolina, Charleston, South Carolina, United States
🇺🇸Univ. of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00035568
- Locations
- 🇺🇸
Local Institution, San Antonio, Texas, United States
A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00035542
- Locations
- 🇺🇸
National Institute Of Clinical Research, Los Angeles, California, United States
🇺🇸Driscoll Children's Hospital/Division of Medical Education/William Riley, Corpus Christi, Texas, United States
🇺🇸Metro Health Medical Center, Cleveland, Ohio, United States
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen
- Conditions
- Chronic Hepatitis B
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00035789
- Locations
- 🇺🇸
Local Investigator, Seattle, Washington, United States